[A21-124] Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide and dexamethasone) - Addendum to Commission A21-61
Last updated 04.11.2021
Project no.:
A21-124
Commission:
Commission awarded on 30.09.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with relapsed and refractory multiple myeloma who have received ≥ 2 prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy
Unchanged after addendum: Added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-61 | Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide und dexamethasone) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
04-11-2021 A G-BA decision was published.